Triple therapy ups response in refractory mantle cell lymphomaFebruary 4, 2018Mantle Cell LymphomaIndolent Lymphoma
VcR-CVAD yields high responses, ‘excellent’ survival in MCLJanuary 11, 2018Mantle Cell LymphomaAggressive Lymphomas
BTK inhibitor zanubrutinib active in non-Hodgkin lymphomasJanuary 2, 2018Mantle Cell LymphomaIndolent LymphomaAggressive Lymphomas
VIDEO - New lymphoma drug approvals: Clinical use, future directionsDecember 14, 2017Mantle Cell LymphomaAggressive Lymphomas
VIDEO: Ibrutinib PFS is nearly 3 years in MCL patients who had one prior therapyDecember 13, 2017Mantle Cell LymphomaAggressive Lymphomas
Avapritinib yields high response rate in patients with systemic mastocytosisDecember 10, 2017Myelodysplastic SyndromeMantle Cell Lymphoma
Rituximab key to survival after transplant for mantle cell lymphomaNovember 16, 2017Mantle Cell LymphomaAggressive Lymphomas
Irradiation safe, effective as chemotherapy before cell transplant in mantle cell lymphomaOctober 23, 2017Mantle Cell Lymphoma
VCR regimen showed efficacy in mantle cell and indolent lymphomasOctober 6, 2017Mantle Cell LymphomaIndolent Lymphoma
Plerixafor doesn’t overcome HPC failure in R-hyperCVAD for mantle cell lymphomaSeptember 10, 2017Mantle Cell Lymphoma
